It’s taken 17 years and a long chain of CEOs, but privately held Melinta Therapeutics has nabbed an FDA approval for its antibiotic delafloxacin, which can now be sold as Baxdela.
Melinta announced a little more than a year ago that the antibiotic had proven non-inferior to vancomycin for acute bacterial skin and skin structure infections (ABSSSI). The last switch up in the executive suite at Melinta, once called Rib-X, was when Mary Szela— now CEO of Novelion — was replaced by R&D chief Eugene Sun in 2015.
Baxdela is a fluoroquinolone that exhibits activity against both gram-positive and gram-negative pathogens, including MRSA, in both oral and IV forms.
Melinta is one of a few late-stage developers in this space, looking to address the growing demand for new antibiotics in a world of growing drug resistance. Zavante touted its own win in April, prepping an FDA application. Paratek hit a few days ahead of that biotech. But Cempra has had a major setback to deal with.
The field has its attractions, but it’s not easy, which explains an absence of many large pharma players on the R&D side. There are a number of cheap, generic antibiotics available for frontline use. And any new antibiotic is going to face an uphill battle gaining traction in this market.
“The approximately 3 million patients hospitalized each year in the U.S. with ABSSSI often present treatment challenges owing to their underlying medical conditions, making optimal antibiotic selection difficult. Baxdela provides a treatment option for adult patients with ABSSSI based on its coverage spectrum, IV and oral dosing flexibility, efficacy and safety profile,” said Sun in a prepared statement. “The approval of Baxdela demonstrates FDA’s commitment to making new and effective antibiotics available to address unmet needs for hospitalized ABSSSI patients.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 33,300+ biopharma pros who read Endpoints News by email every day.Free Subscription